CompletedPhase 2NCT01614795
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
Studying Alveolar rhabdomyosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Lars Wagner, MDChildren's Oncology Group
- Intervention
- Cixutumumab(biological)
- Enrollment
- 46 enrolled
- Eligibility
- 1-30 years · All sexes
- Timeline
- 2012 – 2014
Study locations (30)
- Children's Hospital of Alabama, Birmingham, Alabama, United States
- University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Loma Linda University Medical Center, Loma Linda, California, United States
- Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Children's Hospital and Research Center at Oakland, Oakland, California, United States
- Children's Hospital of Orange County, Orange, California, United States
- Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States
- UCSF Medical Center-Parnassus, San Francisco, California, United States
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver, Colorado, United States
- Connecticut Children's Medical Center, Hartford, Connecticut, United States
- Yale University, New Haven, Connecticut, United States
- Alfred I duPont Hospital for Children, Wilmington, Delaware, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01614795 on ClinicalTrials.govOther trials for Alveolar rhabdomyosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT05304585Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative RhabdomyosarcomaChildren's Oncology Group
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05071209Elimusertib for the Treatment of Relapsed or Refractory Solid TumorsNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGPHASE3NCT04994132A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk RhabdomyosarcomaChildren's Oncology Group
- RECRUITINGPHASE3NCT06669013Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue SarcomasN.N. Petrov National Medical Research Center of Oncology
- ACTIVE NOT RECRUITINGNCT03296371Genetic Mutational Analysis of Saliva or Buccal Mucosa Samples From Patients With Embryonal or Alveolar RhabdomyosarcomaChildren's Oncology Group
- ACTIVE NOT RECRUITINGPHASE3NCT02567435Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk RhabdomyosarcomaNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGPHASE2NCT00077285Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk RhabdomyosarcomaMemorial Sloan Kettering Cancer Center